NetNews Usenet Archive 1993 #3/NN_1993_3.iso/spool/bionet/scireso/307

Internet Message Format | 1993-01-21 | 45.6 KB

Path: sparky!uunet!paladin.american.edu!howland.reston.ans.net!zaphod.mps.ohio-state.edu!uwm.edu!biosci!NET.BIO.NET!kristoff
From: [e-mail] (Dave Kristofferson)
Newsgroups: bionet.sci-resources
Subject: NIH Guide, vol. 22, no. 3, pt. 4, 22 January 1993
Message-ID: <[e-mail]>
Date: 22 Jan 93 00:21:54 GMT
Sender: [e-mail]
Distribution: bionet
Lines: 1083


$$XID RFA DK9316 DK-93-16 P1O1 *****************************************

SERUM, URINE, AND SEMEN INDICATORS OF BENIGN PROSTATE DISEASE

NIH GUIDE, Volume 22, Number 3, January 22, 1993

RFA:  DK-93-16

P.T. 34; K.W. 0705075, 0785220, 0745020

National Institute of Diabetes and Digestive and Kidney Diseases

Letter of Intent Receipt Date:  February 18, 1993
Application Receipt Date:  March 26, 1993

PURPOSE

The Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of
the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) is soliciting grant applications for support of research
studies on factors in serum, urine, and semen that indicate the
presence and progression of the benign diseases of the prostate,
specifically benign prostatic hyperplasia (BPH) and chronic
abacterial prostatitis (CAP).

The purpose of this request is to solicit applications that propose
to investigate factors in the serum, urine, and semen that indicate
the presence of the benign diseases of the prostate growth, that can
quantify any changes in these benign diseases, and that can
differentiate between these benign diseases and malignant prostate
changes.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas. This Request
for Applications (RFA), Serum, Urine, and Semen Indicators of Benign
Prostatic Diseases is related to the priority area of diabetes and
chronic disabling conditions.  Potential applicants may obtain a copy
of "Healthy People 2000" (Full Report:  Stock No. 017-001-00474-0) or
"Healthy People 2000" (Summary Report:  Stock No. 017-001-00473-1)
through the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325 (telephone [phone]).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic and foreign, for-profit and
non-profit organizations, public and private, such as universities,
colleges, hospitals, laboratories, units of State and local
governments, and eligible agencies of the Federal government.
Minority individuals and women are encouraged to submit as Principal
Investigators.

MECHANISM OF SUPPORT

Support of this program will be through the NIH research project
grant (R01).  Responsibility for the planning, direction, and
execution of the proposed project will be solely that of the
applicant.  Awards will be administered under PHS grants policy as
stated in the PHS Grants Policy Statement.

This RFA is a one-time solicitation.  Generally, future unsolicited
competing continuation applications will compete with all
investigator-initiated applications and be reviewed according to the
customary peer review procedures.  The total requested project period
for applications submitted in response to this RFA may not exceed
five years.  Applicants must limit their requests to not more than
$160,000 direct costs for the initial budget period.  The earliest
possible award date will be September 30, 1993.

FUNDS AVAILABLE

For FY 1993, $1,000,000 will be committed by the NIDDK to fund
applications submitted in response to this RFA.  It is anticipated
that five to eight awards will be made by the NIDDK.  However, this
funding level is dependent upon the receipt of a sufficient number of
applications of high scientific merit.  Although this program is
provided for in the financial plans of the NIDDK the award of grants
pursuant to this RFA is also contingent upon the availability of
funds for this purpose.

It is anticipated that the majority of applications submitted, and
ultimately funded, in response to this RFA will be for the support of
new projects.

RESEARCH OBJECTIVES

Background

The benign diseases of the prostate, i.e., benign prostatic
hyperplasia and chronic abacterial prostatitis, affect untold numbers
of men of all ages.  These diseases are generally insidious in their
onset and, when they have advanced to the symptomatic stage, either
become more difficult to treat, have a greater morbidity associated
with treatment, or have progressed to the point where symptoms cannot
be adequately resolved with treatment.  In addition, it has been
suggested by some investigators that these benign diseases are
precursors of malignant cellular change in the prostate.

Applications to solely study indicators of malignant prostate growth,
or that focus primarily on malignant growth are not within the scope
of this RFA.

Program project grant applications (P01) will not be accepted in
response to this RFA.

SPECIAL REQUIREMENTS

SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS

NIH policy is that applicants for NIH clinical research grants and
cooperative agreements are required to include minorities in study
populations so that research findings can be of benefit to all
persons at risk of the disease, disorder or condition under study;
special emphasis must be placed on the need for inclusion of
minorities in studies of diseases, disorders and conditions which
disproportionately affect them.  This policy is intended to apply to
males of all ages.  If minorities are excluded or inadequately
represented in clinical research, particularly in proposed
population-based studies, a clear compelling rationale must be
provided.

The composition of the proposed study population must be described in
terms of racial/ethnic group.  In addition, racial/ethnic issues must
be addressed in developing a research design and sample size
appropriate for the scientific objectives of the study.  This
information must be included in the form PHS 398 (rev. 9/91) in Item
4 (Research Design and Methods) of the Research Plan AND summarized
in Item 5, Human Subjects. Applicants are urged to assess carefully
the feasibility of including the broadest possible representation of
minority groups.  However, NIH recognizes that it may not be feasible
or appropriate in all research projects to include representation of
the full array of United States racial/ethnic minority populations;
i.e., Native Americans [including American Indians or Alaskan
Natives], Asian/Pacific Islanders, Blacks, Hispanics.

The rationale for studies on single minority population groups should
be provided.

For the purpose of this policy, clinical research is defined as human
biomedical and behavioral studies of etiology, epidemiology,
prevention [and preventive strategies], diagnosis, or treatment of
diseases, disorders or conditions, including but not limited to
clinical trials.

The usual NIH policies concerning research on human subjects also
apply.  Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded.  However,
every effort should be made to include human tissues from
racial/ethnic minorities when it is important to apply the results of
the study broadly, and this should be addressed by applicants.

If the required information is not contained within the application,
the application will be returned without review.

Peer reviewers will address specifically whether the research plan in
the application conforms to these policies.  If the representation of
minorities in a study design is inadequate to answer the scientific
question(s) addressed AND the justification for the selected study
population is inadequate, it will be considered a scientific weakness
or deficiency in the study design and reflected in assigning the
priority score to the application.

All applications for clinical research submitted to NIH are required
to address these policies.  NIH funding components will not award
grants or cooperative agreements that do not comply with these
policies.

LETTER OF INTENT

Potential applicants are strongly encouraged to submit a letter of
intent by February 18, 1993.  The letter of intent need only include:
(1) names of the Principal Investigator/program director and
principal collaborators, (2) descriptive title of the potential
application, (3) identification of the organization(s) involved, and
(4) the number and title of the RFA in response to which the
application may be submitted.

Although a letter of intent is not required, is not binding, and does
not enter into the review of subsequent applications, the information
that it contains is helpful in planning for the review of
applications.  It allows NIDDK staff to estimate the potential review
workload and to avoid conflict of interest in the review.

The letter of intent is to be sent to:

Chief, Review Branch
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 605
5333 Westbard Avenue
Bethesda, MD  20892

APPLICATION PROCEDURES

The research grant application form PHS 398 (rev. 9/91) is to be used
to apply for these grants.  The form is available from most
institutional offices of sponsored research and from the Office of
Grants Inquiries, Division of Research Grants, National Institutes of
Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone
[phone].

For developing programs that deal with clinical populations,
applicants may wish to consider utilization of General Clinical
Research Center (GCRC) facilities. More information on the GCRC
program is available from Dr. Judith Vaitukaitis at the National
Center for Research Resources, telephone: [phone].

The RFA label available in the application form must be affixed to
the bottom of the face page.  Failure to use this label could result
in delayed processing of the application such that it may not reach
the review committee in time for review.  In addition, the RFA title
and number must be typed on line 2a of the face page of the
application form and check the YES box.

Submit a signed, typewritten original of the application, including
the Checklist, and three signed, exact
photocopies, in one package to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**

At time of submission, two additional copies of the application must
also be sent under separate cover to:

Chief, Review Branch
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 605
Bethesda, MD  20892

Applications must be received by March 26, 1993.  If an application
is received after that date, it will be returned to the applicant.
The Division of Research Grants (DRG) will not accept any application
in response to this announcement that is essentially the same as one
currently pending initial review, unless the applicant withdraws the
pending application.  However, it is allowable to submit the same
project as both an R01 and as a component project of a program
project.  The DRG will not accept any application that is essentially
the same as one already reviewed.  This does not preclude the
submission of substantial revisions of applications previously
reviewed.  Such applications must not only include an introduction
addressing the previous critique but also be responsive to this RFA.

REVIEW CONSIDERATIONS

Upon receipt, applications will be reviewed by the DRG for
completeness. Incomplete applications will be returned to the
applicant without further consideration.  Evaluation for
responsiveness to the program requirements and criteria stated in the
RFA is an NIDDK staff function.  If the application is not responsive
to the RFA, the staff will contact the applicant to determine whether
it should be returned to the applicant, or held until the next
regular receipt date and reviewed in competition with all other
applications.

Those applications that are complete and responsive will be evaluated
in accordance with the criteria stated below for scientific/technical
merit by an appropriate peer review group convened by the NIDDK.
Applications may be subjected to triage by an NIDDK peer review group
to determine their scientific merit relative to other applications
received in response to this RFA.  If the number of applications is
large compared to the number of awards to be made, a preliminary
scientific peer review may be conducted and applications withdrawn
from further competition when they are not competitive for the award.
The NIDDK staff will notify the applicant and institutional official
of this action.

Those applications judged to be competitive will be reviewed for
scientific and technical merit in accordance with the usual NIH peer
review procedures by an initial review group specifically convened
for this RFA.  Following this review, the applications will be given
a secondary review by the National Diabetes and Digestive and Kidney
Diseases Advisory Council unless not recommended for further
consideration by the initial review group.

Review criteria for RFAs are generally the same as those for
unsolicited research grant applications.

o  scientific/technical merit criteria specific to the objectives of
the RFA;

o  scientific, technical, or medical significance and originality of
proposed research;

o  appropriateness and adequacy of the experimental approach and
methodology proposed to carry out the research;

o  qualifications and research experience of the Principal
Investigator and staff, particularly but not exclusively in the area
of the proposed research;

o  availability of resources necessary to perform the research;

o  appropriateness of the proposed budget and duration in relation to
the proposed research; and

o  if an application involves activities that could have an adverse
effect upon humans, animals, or the environment, the adequacy of the
proposed means for protecting against or minimizing such effects.

AWARD CRITERIA

Funding decisions will be made based on the initial review group and
national advisory council recommendations, program relevance and
availability of funds.

The anticipated date of award is September 30, 1993.

INQUIRIES

Written and telephone inquiries concerning this RFA are encouraged.
Direct inquiries regarding programmatic issues to:

Ralph L. Bain, Ph.D.
Deputy Director, Urology Program
Division of Kidney, Urologic, and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 3A-05
Bethesda, MD  20892
Telephone:  [phone]

Inquiries regarding fiscal matters should be directed to:

Ms. Trude McCain
Grants Management Specialist
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 649
Bethesda, MD  20892
Telephone:  [phone]

Schedule

Letter of Intent Receipt Date:  February 18, 1993
Application Receipt Date:       March 26, 1993
Initial Review:                 June 1993
Second Level Review:            September 1993
Anticipated Date of Award:      September 30, 1993

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance No. 93.849 (NIDDK) .  Awards are made under authorization
of the Public Health Service Act, Title IV, Part A (Public Law
78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and
administered under PHS grants policies and Federal Regulations 42 CFR
52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or
Health Systems Agency review.


$$XID RFA RR93001 RR-93-001 P1O1 ***************************************

INSTITUTIONAL DEVELOPMENT AWARD

NIH GUIDE, Volume 22, Number 3, January 22, 1993

RFA:  RR-93-001

P.T. 14; K.W. 0710030, 1014006

National Center for Research Resources

Letter of Intent Receipt Date:  March 12, 1993
Application Receipt Date:  April 13, 1993

PURPOSE

The National Center for Research Resources (NCRR) invites grant
applications for the Institutional Development Award (IDeA) program.
The National Institutes of Health (NIH) IDeA is a merit-based, peer
reviewed program initiated in response to Congressional intent to
broaden the geographical distribution of NIH funding for biomedical
research.  Primary goals of the IDeA program are to:  (1) enhance the
competitiveness of investigators from research institutions in the
NIH eligible states within the peer review system and (2) to increase
the probability of long-term growth of NIH competitive funding to
investigators at institutions from the eligible states.  This Request
For Application (RFA) describes a one-year planning and development
program to increase, strengthen, and sustain the biomedical research
competitiveness of institutions within selected states.  The program
will be similar in some aspects to the Experimental Program to
Stimulate Competitive Research (EPSCoR) initiated by the National
Science Foundation (NSF).  For example, all applications must be
reviewed by state-based EPSCoR committees or comparable committees to
select eligible institutions to submit applications on behalf of
investigators.  Also, in response to specific Congressional intent,
all accredited Schools of Chiropractic Medicine are invited to apply.

ELIGIBILITY REQUIREMENTS

Because of the pilot nature of this activity and the limited amount
of funds available, eligibility will be limited to all NSF-EPSCoR
states and all those states with a total funding level of less that
$30 million from the NIH in FY 1992.  Eligible institutions include
domestic for-profit and non-profit organizations public and private,
such as universities, colleges, hospitals, research foundations, and
laboratories.  It is the responsibility of the State-EPSCoR
committees to select institutions in their states that have limited
NIH funding, but for which both the states and the institutions have
a mutual agreement and commitment to the development of the
biomedical research infrastructure.  Only one application can be
submitted per state.  IDeA eligible states under these criteria are
listed in Appendix 1.

Applications from Schools of Chiropractic Medicine do not have to be
reviewed at the state level but only one application can be submitted
per institution.  Eligible Schools of Chiropractic Medicine are
listed in Appendix 2.  Applications from institutions with
significant minority enrollments are especially encouraged.

MECHANISM OF SUPPORT

This RFA will use the grant-in-aid for exploratory grants (P20).
Applicants will be responsible for the planning, direction, and
content of the proposed programs.  Awards will be administered under
Public Health Service (PHS) grants policy as stated in the PHS Grants
Policy Statement.

FUNDS AVAILABLE

This RFA is a one-time solicitation.  Up to $750,000 will be
available from NCRR in FY 1993 to support this initiative.  Subject
to the receipt of a sufficient number of meritorious applications, it
is anticipated that approximately six to eight one-year awards will
be made.

Although the total project period for these applications may not
exceed one year, it is expected that institutional development goals
will be proposed beyond that period. Direct costs requested for this
one-year planning phase award should not exceed $100,000.  To ensure
that adequate resources are available, IDeA awards require a minimum
of one-to-one non-Federal match.  Each dollar of NIH support
requested must be matched by at least one dollar from state,
institutional, or private sector sources.  In-kind contributions
(faculty or technical support salaries, facilities, equipment) may
not be used to satisfy the one-to-one minimum matching funds
requirement.  This type of support is considered part of the
state/institutional commitment to achieve research competitiveness at
the national level.  Indirect costs will be provided.  The
anticipated award date is September 30, 1993.  This initiative is
provided for in the FY 1993 NCRR appropriation; future awards will be
contingent upon the availability of funds for the purpose.

RESEARCH OBJECTIVES

Background

The mission of the NIH is to expand fundamental knowledge about the
nature and behavior of living systems, to apply that knowledge to
extend the health of human lives, and to reduce the burdens resulting
from disease and disability.  Through its institutes and centers,
each with its own research mission, the NIH provides funds for
research and research training activities to institutions.  Each
funding unit makes awards on a competitive basis after applications
are assessed for technical and scientific merit and program relevance
through a two-stage process of peer-review.

For many years, the NIH has made a special effort to stimulate
research in educational institutions that traditionally have not
received significant levels of funding through the NIH.  The Academic
Research Enhancement Award (AREA) program, initiated in 1985,
stimulates the research environment of institutions by providing
support to faculty at domestic institutions offering baccalaureate or
advanced degrees in the health-related sciences.

This program will address the same objectives, but on a state-wide
level.  NCRR acknowledges that, due to variability among potential
applications, the size and scope of the IDeA program will depend in
large part upon the current size and extent of the biomedical
research environment of the applicant institutions.  It is
recommended that, in order to achieve maximum impact of the available
funds, institutions propose innovative research activities that will
stimulate sustainable improvements in the capacities of institutions
in eligible states to compete successfully for NIH funds and to
enhance the research competitiveness of the institutions in future
years.

Example of activities include:

o  faculty development to develop and maintain competitiveness in
biomedical research within their institutions

o  mainstreaming of junior faculty into regular research programs of
the NIH

o  development of multidisciplinary approaches to building a
broad-based research infrastructure at the institution

In general, the applicant institution should provide evidence that an
IDeA award is necessary to enhance its capability for health-related
research and that there are state/institutional or other private
resources committed to improve and sustain their programs.

The research plan should provide sufficient information to allow the
reviewers to assess the program in terms of the stated Review
Criteria.  The narrative portion should provide:  (a) comprehensive
information about the institution's current involvement in biomedical
and health-related behavioral research; (b) biographical data for all
health scientists and related administrative personnel; (c) a
description of the long-range institutional research development
goals to be achieved; (d) a complete description of the specific
activities to achieve the goals of the program, including an
evaluation plan to measure the progress of the program and the
procedures to sustain the achievements obtained with IDeA funds after
termination of the award; (e) a description of the administrative
mechanisms to organize and oversee implementation of the plan; (f)
evidence of the institution's commitment to achievement of the
program goals; (g) a detailed budget explaining and justifying the
support requested; and (h) countersigned letters of commitment from
those persons whose cooperation is critical to the success of the
program including a statement from the institution's highest ranking
administrative authority explaining how the IDeA application is
consistent with the institution's (and/or the state's) long-range
objectives to enhance the biomedical research infrastructure and to
achieve research competitiveness at the national level.

Specific research projects (e.g., pilots studies, start-up support)
must be described in sufficient detail to permit evaluation of
scientific merit of each project.  This information is necessary to
justify an IDeA award and to provide evidence that the research that
will result from the award will be of high quality and be likely to
compete successfully for future federal funding.

Allowable Costs

In general, the direct costs listed in the PHS Grants Policy
Statement as allowable for research grants are also allowable for
IDeA applications.  Funds requested for the IDeA Program may be used
to support the following:

o  recruitment of research personnel, if consistent with applicable
cost principles
o  development of research data to be included in research grant
applications submitted to NIH for support through established support
mechanisms
o  development of research skills by investigators
o  research salary support of key investigators
o  consultants
o  establishment of research laboratories
o  central shared equipment and other research resources
o  alterations and renovations (modest level)
o  grant related support personnel
o  other direct costs of development of institutional research
capability

Costs Not Allowable

o  training
o  construction
o  salary for teaching and other non-research activities
o  institutional grants and contract office, central accounting, and
similar activities
o  research project support for established investigators unless
necessary for temporary start-up costs as in recruitment, or
relocation or initiation of new research directions

Support provided through the IDeA program may not replace existing
state, institutional or Federal research support.  IDeA support may
not be used to maintain current biomedical activities, but must be
used to develop innovative ways to enhance the quality and
competitiveness of the state institutional biomedical research base.

LETTER OF INTENT

Prospective applicants are asked to submit by March 12, 1993, a
letter of intent that includes a descriptive title of the proposed
program, the name, address, and telephone number of the Principal
Investigator, and the number and title of the RFA in response to
which the application may be submitted.

Although a letter of intent is not required, is not binding, and does
not enter into the review of subsequent applications, the information
contained is helpful in planning for the review of applications.  It
allows NIH staff to estimate the potential review workload and to
avoid possible conflict of interest in the review.

The letter of intent is to be sent to Dr. Marjorie A. Tingle at the
address listed under INQUIRIES.

APPLICATION PROCEDURES

Applications are to be submitted using form PHS 398 (rev. 9/91).
These forms are available in most institutional business and
sponsored program offices and may be requested from the Office of
Grants Inquiries, Division of Research Grants, National Institutes of
Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone
[phone].

Applications must follow the instructions provided in the PHS 398
form and the following:

Application Face Page -

The RFA label in the PHS 398 kit must be affixed to the bottom of the
face page of the application.  Failure to use this label could result
in delayed processing of the application such that it may not reach
the review committee in time for review.  In addition, the RFA number
and title must be typed on line 2a of the face page form, the "YES"
box must be checked, and "P20" typed in item 2b.

Item 6 - Dates of Entire Proposed Project Period.  The total proposed
project period should begin on September 30, 1993, and may not exceed
one year in length.

Form Page 4 - Detailed Budget for Initial Budget Period

The budget presented should reflect the applicant's estimate of
activity costs for the one-year period.

Form Page 5 -

Budget for Entire Proposed Project Period - Not applicable; do not
complete.

Justification - Follow the instructions provided.

The signed, typewritten original of the application, including the
Checklist, and three exact photocopies of the signed application must
be submitted to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**

At the time of submission, two additional copies of the application
must also be sent to Dr. Marjorie A. Tingle at the address noted
below.

Applications must be submitted by April 13, 1993.  Applications
submitted after this date will be returned to the applicant.

REVIEW CONSIDERATIONS

Review Procedure

Review of IDeA applications for scientific and technical merit will
be performed by an ad hoc review committee convened by the Office of
Review, NCRR.  Applications will undergo a second level of review by
the National Advisory Research Resources Council.

Applications in response to this solicitation will be reviewed using
the usual NIH peer review procedures.

Criteria for review of applications include the following:

1.  What are the merits of the research development goals to be
achieved by the requested IDeA award?

2.  What are the merits of the plan proposed to achieve the research
development goals?

3.  What is the quality of the research to be conducted during the
award?

Criteria for review for pilot or start up studies include:

o  Significance and relevance of the proposed research problem;
potential for publishable results and continued future funding.

o  Appropriateness of research plan, including specific aims,
experimental design, methodology, consideration of alternatives, data
analysis, scope and timetable.

o  Adequacy of resources, including background and training of
principal investigator and other personnel, availability and
suitability of specialized facilities and equipment.

o  Relevance of proposed project to institutional plan for expansion
of biomedical research capacity.

4.  What are the research qualifications of existing and proposed
personnel related to the IDeA award?

5.  Is the requested time and budget justified?

6.  What are the administrative strengths of the applicant
institution?

7.  What is the evidence of the commitment of the applicant
institution and the state to the achievement of the research
development goals and to sustaining those achievements?

8.  What is the probability that the research development goals will
be achieved and sustained, and that high quality health research will
result?

Special emphasis will be placed on the impact of the proposed project
on the institution(s) and the state and its potential to obtain
additional NIH research support to continue and expand its
activities.

AWARD CRITERIA

In making funding decisions, NCRR will give consideration to ensure
program balance among the various types of programs and/or geographic
distribution.  Consideration will also be given to focus on reaching
minority, rural and other underserved and disadvantaged individuals.

INQUIRIES

Prospective applicants are advised to communicate with NCRR program
and grants management staff who are available to assist applicants to
ensure that the objectives, structure and budget format for the
proposal are acceptable.

Written and telephone inquiries concerning this RFA are encouraged.
The opportunity to clarify any issues or questions from potential
applicants is welcome.

Direct inquiries regarding programmatic issues to:

Dr. Marjorie A. Tingle
Director, Biomedical Research Support Program
National Center for Research Resources
Westwood Building, Room 10A11
Bethesda, MD  20892
Telephone:  [phone]

Direct inquiries regarding fiscal matters to:

Ms. Mary V. Niemiec
Office of Grants and Contracts Management
National Center for Research Resources
Westwood Building, Room 849
Bethesda, MD  20892
Telephone:  [phone]

AUTHORITY AND REGULATIONS

Awards will be made under authorization of the Public Health Service
Act, Title III, Part A (Public Law 78-410, as amended, 42 USC 241)
and administered under PHS grants policies and Federal Regulations 42
CFR 52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or
Health Systems Agency Review.

APPENDIX I

Alabama              Maine                  South Carolina
Alaska               Mississippi            South Dakota
Arkansas             Montana                Vermont
Delaware             Nebraska               West Virginia
Hawaii               Nevada                 Wyoming
Idaho                New Mexico
Kansas               North Dakota
Kentucky             Oklahoma
Louisiana            Puerto Rico

APPENDIX II

The Council on Chiropractic Education Accredited Status Holding
Institutions:

Cleveland Chiropractic College
Kansas City, Missouri

Cleveland Chiropractic College of Cleveland University -Los Angeles
Los Angeles, California

Life Chiropractic College
Marietta, Georgia

Life Chiropractic College - West
San Lorenzo, California

Logan College of Chiropractic
Chesterfield, Missouri

Los Angeles College of Chiropractic
Whittier, California

National College of Chiropractic
Lombard, Illinois

New York Chiropractic College
Seneca Falls, New York

Northwestern College of Chiropractic
Bloomington, Minnesota

Palmer College of Chiropractic - West
Sunnyvale, California

Palmer College of Chiropractic
Davenport, Louisiana

Parker College of Chiropractic
Dallas, Texas

Texas Chiropractic College
Pasadena, Texas

Western States Chiropractic College
Portland, Oregon


$$XID RFA CA9318 CA-93-18 P1O1 *****************************************

BREAST CANCER EDUCATION MINI-SUMMITS

NIH GUIDE, Volume 22, Number 3, January 22, 1993

RFA:  CA-93-18

P.T. 34; II; K.W. 0715035, 0403004, 0502017

Application Receipt Date:  May 7, 1993

PURPOSE

The purpose of this Request for Applications (RFA) is to provide
support for the planning, implementation, and evaluation of Breast
Cancer Education Mini-Summits.  These mini-summits are intended as
follow-up to other breast cancer education programs designed to
educate and encourage leaders of community organizations, businesses,
and/or health organizations to establish breast cancer education and
screening programs, such as the Breast Cancer Educations Summits
funded under RFA CA-91-27.  The present RFA provides applicant
institutions opportunities to develop and conduct focused programs
that are tailored to the needs of more defined target audiences, as
opposed to the large-scale summits that will be funded under a
different RFA and will provide a comprehensive introduction to
screening and education programs aimed at a broad audience.

The overall intent of the mini-summits and large-scale summits is the
same:  to educate and motivate community organizations, business, and
health organizations to establish breast cancer education and
screening programs in the community.  The ultimate aim of all summits
is to reach all women, placing special emphasis on women at high risk
of breast cancer and populations that are medically underserved
and/or hard-to-reach, with information about risks for breast cancer,
the potentially life-saving methods that may detect the cancer in its
most treatable, early stages, and information about how to seek
state-of-the-art treatment.

This RFA is limited to:  (1) NCI-Designated Cancer Centers with P30
grants, (2) institutions with NCI P20 planning grants for prospective
cancer centers, and (3) other institutions with a broad base of
grant-supported research in basic, clinical and prevention and
control science, and that have demonstrated prior experience in
conducting intensive and detailed breast cancer education programs
for one or a few of the target audiences of this RFA.  The target
audiences are community organizations, businesses, government and
other health organizations, and intermediaries that reach medically
underserved and hard-to-reach women.  Relevant medical and scientific
expertise, and the information and education resources, in place and
operational, will best qualify the applicant institutions to (1) plan
and conduct mini-summits with a content that is of greatest practical
and educational benefit and to (2) identify and reach target
audiences of this RFA.  The applicant institutions should have strong
ties within the community with voluntary community organizations,
corporate leaders, state and local health departments, and other
intermediaries with access to medically underserved and hard-to-reach
populations.  This access ensures dissemination of highly relevant
information to the target audiences and the greatest possibility for
achieving an impact on establishment of new breast cancer education
and screening programs.

Qualified institutions are invited to submit applications for hosting
Breast Cancer Education Mini-Summits with NCI and other national and
regional sponsors of the initiative.  Applicants should also include,
when possible, the local Cancer Information Service (CIS) in the
plans for the mini-summit; the CIS can be used as an information
resource for questions concerning early detection and treatment.  The
local and/or divisional chapter of the American Cancer Society should
be included in the mini-summit plans.  Also, the planning committee
for the mini-summit should include minority representatives, as well
as representatives from community organizations with access to the
medically underserved.

NCI will provide for the attendees at each mini-summit written
educational materials to assist organizations in promoting early
detection, to guide businesses in developing worksite programs, to
encourage women to follow NCI recommended breast cancer screening
guidelines and, if needed, to aid in seeking state-of-the art
treatment.  To assist in developing a mini-summit proposal, NCI has
available a "how to host a summit" guide, which was developed for the
large-scale summits but provides information useful in developing any
type of breast cancer education program.  The guide is available from
the NCI Program Directors. In addition, individuals from institutions
eligible to apply for this RFA may attend a workshop about conducting
breast cancer summits, that will be held in Washington, DC on
February 23, 1993.

Pre-registration is required through the contact named in INQUIRIES
below.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Breast Cancer Education Mini-Summits, is related to the priority area
of cancer.  Potential applicants may may obtain a copy of "Healthy
People 2000" (Full Report:  Stock No. 017-001-00474-0) or "Healthy
People 2000"  (Summary Report:  Stock No. 017-001-00473-1) thorough
the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325 (202-783-3238).

ELIGIBILITY

Eligible institutions may apply for a grant under both this RFA and
RFA CA-93-17 to host a large-scale summit.  However, the geographic
location of cancer centers will be considered to allow broad coverage
of the U.S. population through both the large-scale and mini-summits.
In addition, for this RFA, consideration will be given to the
intended target audiences to ensure that model, or prototype,
mini-summits are developed and conducted that reach all the audiences
of this RFA:  businesses, community organizations, government and
other health organizations, and intermediaries who have access to
medically underserved and hard-to-reach populations.

MECHANISM OF SUPPORT

The administrative and funding mechanism to be used to support these
summits will be the Conference Grant Award (R13).  Responsibility for
the planning, direction, and execution of the proposed project will
be solely that of the applicant.  The total project period for
applications submitted in response to the present RFA may not exceed
one year.  No more than $7,500 will be awarded to a single
institution.  The summits are well-spaced within the time frame of
October 1993 and July 1994.

Applicants are invited to attend a one-day workshop on planning and
conducting a breast cancer summit meeting that will be held in
Washington, DC on February 23, 1993.  Pre-registration is required
through the contact named in INQUIRIES below.

The funds and resources provided by NCI must be used for information
and education purposes only and not for fund-raising activities.

APPLICATION PROCEDURES

The research grant application form PHS-398 (revised 9/91) is to be
used in applying for these grants.  These forms are available at most
institutional offices of sponsored research; from the Office of
Grants Inquiries, Division of Research Grants, National Institutes of
Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone
301-496-7441; and from the NCI Program Director named below.
Applicants may find information on the requirements for conference
grants and supplemental instructions for application form PHS-398 in
the publication on "Support of Scientific Meetings," U.S. Department
of Health and Human Services, August 1988, 8 pp., which can be
obtained from the Office of Grants Inquiries or the Grants Management
contact noted below.

The RFA label must be affixed to the bottom of the face page of the
original copy of the application.  Failure to use this label could
result in delayed processing of the application such that it will not
reach the review committee in time for review.  In addition, the RFA
number and title must be typed on line 2a of the face page of the
application, and the YES box must be marked.

Submit a signed, typewritten original of the application, including
the Checklist, and three signed, photocopies in one package to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**

At time of submission, send two additional copies of the application
to:

Ms. Toby Friedberg, Referral Officer
Division of Extramural Activities
National Cancer Institute
Executive Plaza North, Room 650
6130 Executive Boulevard
Rockville, MD  20892

Applications must be received by May 7, 1993.  If an application is
received after that date, it will be returned to the applicant
without review.  The Division of Research Grants (DRG) will not
accept any application in response to this announcement that is
essentially the same as one currently pending initial review, unless
the applicant withdraws the pending application.  The DRG will not
accept any application that is essentially the same as one already
reviewed.  This does not preclude the submission of substantial
revisions of applications already reviewed, but such applications
must include an introduction addressing the previous critique.

REVIEW CONSIDERATIONS

Upon receipt, applications will be reviewed for completeness by DRG
and responsiveness by the NCI. Incomplete and/or non-responsive
applications will be returned to the applicant without further
consideration.

Those applications judged to be responsive will be further evaluated
according to the review criteria stated below for scientific and
technical merit by an appropriate peer review group convened by the
Division of Extramural Affairs, NCI.  The second level of review will
be conducted by the Executive Committee of the NCI to consider the
special requirements as noted in Section VII and the priorities of
the National Cancer Program.

Proposals responsive to this competitive solicitation will be
reviewed in accordance with the criteria stated below.

1.  The technical merit of the proposed mini-summit, including the
organization and agenda, as well as the proposed evaluation and
follow-up for the program.

2.  The institutional base of grant-supported research in basic,
clinical and prevention and control science.

3.  The institutional expertise available for state-of-the-art cancer
treatment, follow-up, information, and education.

4.  The qualifications and experience of the Principal Investigator
and staff.

5.  The applicant's plans for, and demonstrated access to, minorities
and hard-to-reach medically underserved populations and an
understanding of their needs in order to plan and implement breast
cancer education and/or screening programs.

6.  Demonstration of an understanding of the barriers that may impede
the target audience(s) in developing and implementing breast cancer
education and/or screening programs.

7.  Demonstration of an understanding of the obstacles to access and
utilization of breast cancer education period of support for each
approved application.  No more than $7,500 in total direct costs will
be awarded to a single institution.

AWARD CRITERIA

The anticipated date of award is July 1993.  The primary criteria for
award will be technical merit reflected in the priority score.
However, the geographic location of the cancer centers will be
considered to allow for the broadest coverage of the U.S. population.
In addition, the intended target audience(s) will be considered to
ensure that, taken together, model mini-summits are developed and
conducted that reach all the target audiences of this RFA:  business,
community organizations, government health agencies, and
intermediaries who have access to medically underserved and
hard-to-reach women.

INQUIRIES

Written and telephone inquiries concerning this RFA are encouraged.
The opportunity to clarify any issues or questions from potential
applicants is welcome.

Direct inquiries on programmatic issues to:

Linda M. Muul, Ph.D.
Special Assistant to OCC
Program Director, Cancer Centers Branch
Division of Cancer Biology, Diagnosis and Centers
National Cancer Institute
Executive Plaza North, Room 308
Bethesda, MD  20892
Telephone:  [phone]

Direct inquiries regarding fiscal matters to:

Cynthia Mead
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Room 243
Bethesda, MD  20892
Telephone:  [phone]  Ext. 54

AUTHORITY REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance No. 93.397.  Cancer Centers Support Awards are under
authorization of the Public Health Service Act, Title IV, Part A
(Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and
285) and administered under PHS grants policies and Federal
Regulations 42 CFR 52 and 45 CFR Part 74.  This program is not
subject to the intergovernmental review requirements of Executive
Order 12372 or Health Systems Agency Review.